DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pilsicainide
Pilsicainide
Uniqueness of Pilsicainide in Class Ic Antiarrhythmics Takeshi
CAS Number Index
What Is the Diagnosis?
Ventricular Tachycardia Drugs Versus Devices John Camm St
Jp Xvii the Japanese Pharmacopoeia
Translational Studies on Anti-Atrial Fibrillatory Action of Oseltamivir by Its in Vivo and in Vitro Electropharmacological Analyses
Pharmaceutical Appendix to the Tariff Schedule 2
(12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea
Drugs to Avoid in Brugada Syndrome Patients January 2015
Prolonged Atrioventricular Block and Ventricular Standstill Following
ST Segment Elevation in the Right Precordial Leads Following Administration of Class Ic Antiarrhythmic Drugs
Pilsicainide Intoxication in a Patient with Dehydration
Medical Treatment for Idiopathic VT/Vpcs
Profiles of Aprindine, Cibenzoline, Pilsicainide and Pirmenol in The
Longer Repolarization in the Epicardium at the Right Ventricular Outflow Tract Causes Type 1 Electrocardiogram in Patients with Brugada Syndrome
Acetylcholine-Activated Potassium Channel As a Novel Target for AF Treatment
Flecainide & Propafenone
Top View
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation a Systematic Review of Randomized Controlled Trials
Pharmaabkommen A1 E
Title Inhibitory Effects of Local Anesthetics on the Proteasome And
A Case of Sudden Cardiac Death Due to Pilsicainide-Induced Torsades De
Randomized Crossover Study of the Long-Term Effects of Pilsicainide
A Sodium Channel Blocker, Pilsicainide, Produces Atrial Post-Repolarization Refractoriness Through the Reduction of Sodium Channel Availability
Antiepileptic Drug Transport at the Blood- Brain Barrier, the Role of SLC Transporters
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Krintafel (Tafenoquine Succinate Tablets) FDA Advisory Committee
CAS Number Index
WO 2U11/132171 Al
Tepzz 5 58¥Zb T
Pharmacological Conversion of Persistent Atrial Fibrillation Into Sinus Rhythm with Oral Pilsicainide
Prognostic Significance of the Sodium Channel Blocker Test in Patients with Brugada Syndrome
Supplemental Appendix 3: Study Characteristics
Beneficial Effects of Biatrial Pacing on Cardiac Function in Patients With
Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008)
Harmonized Tariff Schedule of the United States (2006) (Rev
ICD-10-CM Table of Drugs 2019
A Novel SCN5A Mutation Associated with Drug Induced Brugada Type ECG
Assessment of Drug-Induced Proarrhythmias Due to Pilsicainide in Patients with Atrial Tachyarrhythmias
Inhibitory Effects of Tetrandrine on the Na+ Channel of Human Atrial Fibrillation Myocardium
Drug-Induced Brugada Syndrome
A Structure-Based Computational Workflow to Predict Liability And
(12) United States Patent (10) Patent No.: US 7,838,552 B2 Davis Et Al
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Efficacy of Long-Term Flecainide Therapy in Patients With
Two Cases of Pilsicainide Intoxication Showing the Brugada-Type Electrocardiographic Findings and Incessant Wide QRS Tachycardia